Development of Inducible CD19-CAR T Cells with a Tet-On System for Controlled Activity and Enhanced Clinical Safety
Published 2018 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Development of Inducible CD19-CAR T Cells with a Tet-On System for Controlled Activity and Enhanced Clinical Safety
Authors
Keywords
-
Journal
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
Volume 19, Issue 11, Pages 3455
Publisher
MDPI AG
Online
2018-11-05
DOI
10.3390/ijms19113455
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Preclinical Optimization of a CD20-specific Chimeric Antigen Receptor Vector and Culture Conditions
- (2018) Sang Yun Lee et al. JOURNAL OF IMMUNOTHERAPY
- Feasibility of controlling CD38-CAR T cell activity with a Tet-on inducible CAR design
- (2018) Esther Drent et al. PLoS One
- Molecular Approaches to Safe and Controlled Engineered T-cell Therapy
- (2018) R Kalinin et al. Acta Naturae
- CAR T Cells in Solid Tumors: Blueprints for Building Effective Therapies
- (2018) Hannah M. Knochelmann et al. Frontiers in Immunology
- A tandem CD19/CD20 CAR lentiviral vector drives on-target and off-target antigen modulation in leukemia cell lines
- (2017) Dina Schneider et al. Journal for ImmunoTherapy of Cancer
- Remote Controlled CARs: Towards a Safer Therapy for Leukemia
- (2016) C. H. June Cancer Immunology Research
- A Tet-On Inducible System for Controlling CD19-Chimeric Antigen Receptor Expression upon Drug Administration
- (2016) R. Sakemura et al. Cancer Immunology Research
- In Vitro Pre-Clinical Validation of Suicide Gene Modified Anti-CD33 Redirected Chimeric Antigen Receptor T-Cells for Acute Myeloid Leukemia
- (2016) Kentaro Minagawa et al. PLoS One
- CD19-targeted chimeric antigen receptor T-cell therapy for acute lymphoblastic leukemia
- (2015) S. L. Maude et al. BLOOD
- Development of Endothelial-Specific Single Inducible Lentiviral Vectors for Genetic Engineering of Endothelial Progenitor Cells
- (2015) Guanghua Yang et al. Scientific Reports
- Treatment of Metastatic Renal Cell Carcinoma With CAIX CAR-engineered T cells: Clinical Evaluation and Management of On-target Toxicity
- (2013) Cor HJ Lamers et al. MOLECULAR THERAPY
- Combining a CD20 Chimeric Antigen Receptor and an Inducible Caspase 9 Suicide Switch to Improve the Efficacy and Safety of T Cell Adoptive Immunotherapy for Lymphoma
- (2013) Lihua E. Budde et al. PLoS One
- Equipping CAR-Modified T Cells with a Brake to Prevent Chronic Adverse Effects
- (2012) Wei Wang et al. CURRENT GENE THERAPY
- Suicide Gene Therapy to Increase the Safety of Chimeric Antigen Receptor-Redirected T Lymphocytes
- (2012) Monica Casucci et al. Journal of Cancer
- B-cell depletion and remissions of malignancy along with cytokine-associated toxicity in a clinical trial of anti-CD19 chimeric-antigen-receptor-transduced T cells
- (2011) J. N. Kochenderfer et al. BLOOD
- Chimeric Antigen Receptor–Modified T Cells in Chronic Lymphoid Leukemia
- (2011) David L. Porter et al. NEW ENGLAND JOURNAL OF MEDICINE
- Lack of humoral immune response to the tetracycline (Tet) activator in rats injected intracranially with Tet-off rAAV vectors
- (2010) Y Han et al. GENE THERAPY
- Regulation of Retinal Function but Nonrescue of Vision in RPE65-deficient Dogs Treated With Doxycycline-regulatable AAV Vectors
- (2010) Elsa Lhériteau et al. MOLECULAR THERAPY
- Case Report of a Serious Adverse Event Following the Administration of T Cells Transduced With a Chimeric Antigen Receptor Recognizing ERBB2
- (2010) Richard A Morgan et al. MOLECULAR THERAPY
- In vivo gene regulation using tetracycline-regulatable systems
- (2009) Knut Stieger et al. ADVANCED DRUG DELIVERY REVIEWS
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now